Xtrackers Nifty 500 India ETF IND
22.96 USD +0.13 (+0.55%)
At closeNov 5, 2026, 4:00 PM EST
22.96 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
22.95 Day range 23.29
20.52 52-week range 27.40
- YTD
- -7.88%
- 1 year
- -8.91%
News
gurufocus.com Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform HONG KONG, Oct 9, 2026 - (ACN Newswire) - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of T
gurufocus.com AARD DEADLINE NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 AARD DEADLINE NOTICE: Faruqi and Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026PR NewswireNEW YORK,
gurufocus.com AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class ActionPR NewswireSAN FRANCISCO,
gurufocus.com Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadli
gurufocus.com Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 De
gurufocus.com Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadli
gurufocus.com Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith Law Offices of Howard G. Smith reminds investors of the upcoming October 13, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of invest
gurufocus.com Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit [url="]Glancy Prongay Wolke and Rotter LLP[/url] reminds investors of the upcoming October 13, 2026 deadline to file a lead plaintiff motion in the class action f
gurufocus.com Deadline Soon: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit [url="]The Law Offices of Frank R. Cruz[/url] reminds investors of the upcoming October 13, 2026 deadline to participate as a lead plaintiff in the securities f
gurufocus.com AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 [url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (âAardvarkâ
gurufocus.com Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines
gurufocus.com Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia [url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy ag
gurufocus.com JetBlue Launches Largest-Ever Fort Lauderdale Schedule, Reinforcing Long-Term Commitment to South Florida JetBlue (NASDAQ: JBLU) today continued its significant expansion at Fort Lauderdale-Hollywood International Airport (FLL), with the launch of eight nonstop des
gurufocus.com Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program PR News
gurufocus.com Imagion Biosystems' IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review [url="]Imagion Biosystems, Ltd. (ASX: IBX)[/url] has announced that the US Food and Drug Administration (FDA) completed its review of the company's investigati
https://news.bitcoin.com Indian Finance Minister: Crypto Regulation Needs Global Consensus Indian Finance Minister Nirmala Sitharaman advocates for global consensus on cryptocurrency regulation, highlighting the need for international cooperation, particularly within the G20. She noted…
seekingalpha.com Sweden Vs. The U.S. - Which Country's Stock Market Is Winning The Fight Against COVID-19? (OMX:IND) Sweden and the US have approached the Covid-19 pandemic in different ways. Sweden's more open approach has been more gentle on the economy.
seekingalpha.com Lighten Up On The Nasdaq 100 (NDX:IND) There's complete unanimity when it comes to the notion that the 2000 stock market represented an egregious stock bubble.
benzinga.com TSX Venture Exchange Daily Bulletins for August 14, 2009 VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 14, 2009) - /T/ TSX VENTURE COMPANIES BULLETIN TYPE: Cease Trade Order BULLETIN DATE: August 13, 2009 TSX Venture Tier 1 Company A Cease Trade Order…
benzinga.com AVI BioPharma Announces Second Quarter 2009 Financial Results & Corporate Highlights BOTHELL, WA--(Marketwire - August 10, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and six months ending June 30, 2009.…